As MAIT cells were not affected by IFN-β therapy, but strongly reduced by high dose of cyclophosphamide in combination with alemtuzumab treatment followed by autologous stem cell transplantation in MS patients17, one can speculate that besides the non-myeloablative depletion, MAIT cells might be susceptible to ROS upregulated by DMF-mediated glutathione depletion. This evidence concerns the gene IFNB1 and myeloid sarcoma.